Second primary cancers: a retrospective analysis of real world data using the enhanced medical research engine ConSoRe in a French comprehensive cancer center.
Electronic patient records
Medical/health data mining tool
Second primary cancer
Surveillance
Survivors
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
30
11
2020
accepted:
03
06
2021
pubmed:
7
6
2021
medline:
22
9
2021
entrez:
6
6
2021
Statut:
ppublish
Résumé
Second primary cancers (SPC) account for 18% of all cancers. We used the enhanced medical/health data mining tool ConSoRe to search aggregated data, analyze electronic patient records (EPR), and better characterize patients with SPC. This retrospective cohort study used ConSoRe to identify EPRs from patients with SPC referred to the regional cancer center Leon Bérard from 1993 to 2017, and examined characteristics of patients with SPC, frequencies of first primary cancer (FPC) localization in the global population of patients with SPC, and time to SPC. Data set was extracted on January 1, 2018. Among 296,530 EPRs, we identified 157,187 patients with FPC, including 13,002 (8%) patients with SPC. Between 2000 and 2010, the rate of SPC was 34%, and 52% of SPC were identified in the last years (2010-2017). In men, main cancers were head and neck cancer, lymphoma, and prostate carcinoma accounting for 15.6%, 12.8%, and 10.5% of FPC, while the three most common SPC were head and neck cancer (13.2%), lung cancer (11.8%) and lymphoma (9.2%). In women, breast cancers, lymphoma, and skin cancers accounted for 48.8%, 8%, and 5.1% of first cancers, and for 31.1%, 7% and 6% of SPC. The data mining tool ConSoRe contributes to access to real world data, and to better characterize patients with SPC. Expanding such approach to any comprehensive center will allow a global overview of the follow-up of patients with cancer, and help to improve long-term management and adapt surveillance.
Sections du résumé
BACKGROUND
BACKGROUND
Second primary cancers (SPC) account for 18% of all cancers. We used the enhanced medical/health data mining tool ConSoRe to search aggregated data, analyze electronic patient records (EPR), and better characterize patients with SPC.
METHODS
METHODS
This retrospective cohort study used ConSoRe to identify EPRs from patients with SPC referred to the regional cancer center Leon Bérard from 1993 to 2017, and examined characteristics of patients with SPC, frequencies of first primary cancer (FPC) localization in the global population of patients with SPC, and time to SPC. Data set was extracted on January 1, 2018.
RESULTS
RESULTS
Among 296,530 EPRs, we identified 157,187 patients with FPC, including 13,002 (8%) patients with SPC. Between 2000 and 2010, the rate of SPC was 34%, and 52% of SPC were identified in the last years (2010-2017). In men, main cancers were head and neck cancer, lymphoma, and prostate carcinoma accounting for 15.6%, 12.8%, and 10.5% of FPC, while the three most common SPC were head and neck cancer (13.2%), lung cancer (11.8%) and lymphoma (9.2%). In women, breast cancers, lymphoma, and skin cancers accounted for 48.8%, 8%, and 5.1% of first cancers, and for 31.1%, 7% and 6% of SPC.
CONCLUSION
CONCLUSIONS
The data mining tool ConSoRe contributes to access to real world data, and to better characterize patients with SPC. Expanding such approach to any comprehensive center will allow a global overview of the follow-up of patients with cancer, and help to improve long-term management and adapt surveillance.
Identifiants
pubmed: 34091824
doi: 10.1007/s10147-021-01963-3
pii: 10.1007/s10147-021-01963-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1793-1804Informations de copyright
© 2021. Japan Society of Clinical Oncology.
Références
Ye Y, Neil AL, Wills KE et al (2016) Temporal trends in the risk of developing multiple primary cancers: a systematic review. BMC Cancer 16(1):849
doi: 10.1186/s12885-016-2876-y
Pacheco-Figueiredo L, Antunes L, Bento MJ et al (2016) Incidence of second primary cancers in North Portugal-a population-based study. J Cancer Surviv 10(1):142–152
doi: 10.1007/s11764-015-0460-0
AIRTUM working group (2013) Italian cancer figures, report 2013: multiple tumours. Epidemiol Prev 37(4–5 Suppl 1):1–152
Jegu J, Colonna M, Daubisse-Marliac L et al (2014) The effect of patient characteristics on second primary cancer risk in France. BMC Cancer 14:94
doi: 10.1186/1471-2407-14-94
Miller KD, Siegel RL, Lin CC et al (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66(4):271–289
doi: 10.3322/caac.21349
Oeffinger KC, Baxi SS, Novetsky FD et al (2013) Solid tumor second primary neoplasms: who is at risk, what can we do? Semin Oncol 40(6):676–689
doi: 10.1053/j.seminoncol.2013.09.012
Glendenning JL, Barbachano Y, Norman AR et al (2010) Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 116(10):2322–2331
pubmed: 20225230
Donin N, Filson C, Drakaki A et al (2016) Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 122(19):3075–3086
doi: 10.1002/cncr.30164
Wood ME, Vogel V, Ng A et al (2012) Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol 30(30):3734–3745
doi: 10.1200/JCO.2012.41.8681
Bhatia S (2015) Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors. Cancer 121(5):648–663
doi: 10.1002/cncr.29096
Kumar S (2012) Second malignant neoplasms following radiotherapy. Int J Environ Res Public Health 9(12):4744–4759
doi: 10.3390/ijerph9124744
Akhtar N, Bansal JG (2017) Risk factors of Lung Cancer in nonsmoker. Curr Probl Cancer 41(5):328–339
doi: 10.1016/j.currproblcancer.2017.07.002
Chen T, Kharazmi E, Lou J et al (2016) Risk of second primary cancers after malignant mesothelioma and vice versa. Cancer Lett 379(1):94–99
doi: 10.1016/j.canlet.2016.05.034
Ligibel J (2012) Lifestyle factors in cancer survivorship. J Clin Oncol 30(30):3697–3704
doi: 10.1200/JCO.2012.42.0638
Druesne-Pecollo N, Keita Y, Touvier M et al (2014) Alcohol drinking and second primary cancer risk in patients with upper aerodigestive tract cancers: a systematic review and meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 23(2):324–331
doi: 10.1158/1055-9965.EPI-13-0779
Casey JA, Schwartz BS, Stewart WF et al (2016) Using electronic health records for population health research: a review of methods and applications. Annu Rev Public Health 37:61–81
doi: 10.1146/annurev-publhealth-032315-021353
Heudel P, Livartowski A, Arveux P (2016) The ConSoRe project supports the implementation of big data in oncology. Bull Cancer 103(11):949–950
doi: 10.1016/j.bulcan.2016.10.001
Testori A, Cioffi U, De SM et al (2015) Multiple primary synchronous malignant tumors. BMC Res Notes 8:730
doi: 10.1186/s13104-015-1724-5
Delaloge S, Perol D, Courtinard C et al (2016) Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. Ann Oncol 27(9):1725–1732
doi: 10.1093/annonc/mdw260
Coudon T, Hourani H, Nguyen C et al (2018) Assessment of long-term exposure to airborne dioxin and cadmium concentrations in the Lyon metropolitan area (France). Environ Int 111:177–190
doi: 10.1016/j.envint.2017.11.027
Mariotto AB, Rowland JH, Ries LA et al (2007) Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev 16(3):566–571
doi: 10.1158/1055-9965.EPI-06-0782
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29
doi: 10.3322/caac.21254
Miller KD, Nogueira L, Mariotto AB et al (2019) Cancer treatment and survivorship statistics. CA Cancer J Clin. https://doi.org/10.3322/caac.21565
doi: 10.3322/caac.21565
pubmed: 31594027
Choi DK, Helenowski I, Hijiya N (2014) Secondary malignancies in pediatric cancer survivors: perspectives and review of the literature. Int J Cancer 135(8):1764–1773
doi: 10.1002/ijc.28991
Fung C, Fossa SD, Milano MT et al (2013) Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 31(30):3807–3814
doi: 10.1200/JCO.2013.50.3409
Gandaglia G, Karakiewicz PI, Trinh QD et al (2014) Cisplatin-based chemotherapy and the risk of solid tumors in patients with testicular nonseminoma: still a matter of debate. J Clin Oncol 32(11):1167
doi: 10.1200/JCO.2013.53.6482
Liang F, Zhang S, Xue H et al (2017) Risk of second primary cancers in cancer patients treated with cisplatin: a systematic review and meta-analysis of randomized studies. BMC Cancer 17(1):871
doi: 10.1186/s12885-017-3902-4
Shin DW, Baik YJ, Kim YW et al (2011) Knowledge, attitudes, and practice on second primary cancer screening among cancer survivors: a qualitative study. Patient Educ Couns 85(1):74–78
doi: 10.1016/j.pec.2010.09.015
Hamilton W (2009) Five misconceptions in cancer diagnosis. Br J Gen Pract 59(563):441–445
doi: 10.3399/bjgp09X420860
Khan NF, Watson E, Rose PW (2011) Primary care consultation behaviours of long-term, adult survivors of cancer in the UK. Br J Gen Pract 61(584):197–199
doi: 10.3399/bjgp11X561195
Heudel P, Chabaud S, Perol D, Ray-Coquard I, Blay JY (2020) Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer. Ann Oncol 31(12):1773–1775
doi: 10.1016/j.annonc.2020.09.001
Heudel P, Chabaud S, Perol D, Flechon A, Fayette J, Combemale P et al (2021) Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer. ESMO Open 6(1):100044
doi: 10.1016/j.esmoop.2020.100044